Ant International, Mastercard and Visa Initiate Collaboration on Know-Your-Agent Interoperability to Scale Agentic Commerce
SHANGHAI and SINGAPORE, Sept. 10, 2026 /PRNewswire/ -- Ant International, Mastercard, and Visa have begun collaboration on a Know-Your-Agent (KYA) interoperability framework, designed to help card networks, digital wallet ecosystems, agent platforms...
FutureCeuticals , Inc. (FC) and Aura Scientific Resolve Coffee Fruit Patent Dispute, Recognize FC Patent Rights, and Initiate Seamless Transition to CognatiQ®
MOMENCE, Ill., Sept. 3, 2026 /PRNewswire/ -- FutureCeuticals, Inc. (FC) and Aura Scientific (Aura) are pleased to announce the resolution of FutureCeuticals' patent and trademark suit related to Aura's NeuroRush® ingredient and FutureCeuticals'...
Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven Complex Biologics R&D
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 15, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142.HK), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology,...
Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
SHANGHAI and HONG KONG, May 28, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia. HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology...
Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic...
PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101
SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO: Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the...
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study
SHANGHAI, Dec. 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its...
S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b...
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II...